Question 1

Does JPMorgan Chase own SLN stock?

Accepted Answer

Yes. As of its Q3 2026 13F, JPMorgan Chase holds 3,649 shares of SLN (Silence Therapeutics), worth $39,409.

Question 2

How many shares of SLN does JPMorgan Chase own?

Accepted Answer

As of its Q3 2026 13F, JPMorgan Chase holds 3,649 shares of SLN (Silence Therapeutics).

Question 3

What is JPMorgan Chase's SLN position worth?

Accepted Answer

As of its Q3 2026 13F, JPMorgan Chase's SLN position is worth $39,409.

Question 4

Is JPMorgan Chase buying or selling SLN?

Accepted Answer

In Q3 2026, JPMorgan Chase reduced its SLN position by 214 shares (-5.5%).

Question 5

When did JPMorgan Chase first buy SLN?

Accepted Answer

JPMorgan Chase first reported SLN in its Q4 2024 13F and has listed it in 8 quarterly 13F filings.

Quarter	Action	Shares	Change	Value	Weight	Price	Conviction
2026-Q3 Latest	Decreased	3,649	-5.5%	$39,409	0.0%	$10.93	0
2026-Q2	Decreased	3,863	-49.4%	$41,682	0.0%	$10.98	0
2026-Q1	Decreased	7,636	-3.9%	$38,027	0.0%	$5.27	0
2025-Q4	Increased	7,942	+2.3%	$48,287	0.0%	$6.08	14
2025-Q3	Increased	7,766	+6.6%	$40,306	0.0%	$5.19	15
2025-Q2	Decreased	7,283	-79.4%	$42,241	0.0%	$5.80	0
2025-Q1	Increased	35,414	+833.7%	$99,867	0.0%	$2.82	24
2024-Q4	New	3,793	—	$26,096	0.0%	$6.88	29